title: Interaction between the LMWH reviparin and aspirin in healthy volunteers.
abstract: OBJECTIVE
  To investigate potential interactions between reviparin and acetylsalicylic acid (ASA 300 mg o.d. from day 1-5).
  
  
  METHODS
  In an open, randomized, three-way-cross over study nine healthy volunteers received reviparin (s.c. injection of 6300 anti-Xa units) or placebo from days 3 to 5 and acetylsalicylic acid (ASA 300 mg) or placebo from days 1 to 5. Assessments included bleeding time (BT), collagen (1 microg ml-1) induced platelet aggregation (CAG), heptest, plasma antifactor Xa-activity and activated partial thromboplastin time (aPTT).
  
  
  RESULTS
  Median bleeding time at day 5 was 5.5 min after reverparin alone and after ASA alone and was 9.6 min after the combination of reviparin and ASA. ASA treatment reduced CAG from 84% to 40 to 50% of Amax; values after combined treatment of reviparin with ASA were not different from those after ASA alone. aPTT was prolonged to 32 s after reviparin; this effect was not modified if subjects received ASA. Combined treatment with ASA and reviparin had no effect on plasma anti-Xa-activity and heptest compared with reviparin alone.
  
  
  CONCLUSIONS
  We could not entirely exclude a small interaction between reviparin and ASA on bleeding time, but the effect is probably without clinical significance.
authors.affiliation: Institute of Clinical Pharmacology of the J.W.Goethe University, Frankfurt/M, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Klinkhardt
authors.forename: H K
authors.initials: HK
authors.lastname: Breddin
authors.forename: H U
authors.initials: HU
authors.lastname: Esslinger
authors.forename: S
authors.initials: S
authors.lastname: Haas
authors.forename: A
authors.initials: A
authors.lastname: Kalatzis
authors.forename: S
authors.initials: S
authors.lastname: Harder
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology*; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology*; D001760:Bleeding Time; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004347:Drug Interactions; D015951:Factor Xa / Q000378:metabolism; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D010979:Platelet Function Tests
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D015951:Factor Xa; D001241:Aspirin